Cart $0.00 (0)
 
 
Free Sample

TransIT®-2020 Transfection Reagent

A high performance, animal-free, broad spectrum DNA transfection reagent

To inquire about bulk pricing, please call 888-530-0801
International inquiries please call +1-608-441-2852
Return Policy

Select a Size:

MIR 54040.4 mlMIR 54001 mlMIR 54055 x 1 mlMIR 540610 x 1 ml

Catalog number selected: -

-

  • Broad Spectrum DNA Delivery – Achieve high expression in many cell types, including hard to transfect cell lines and primary cells
  • Gentle to Your Cells – Balances high efficiency nucleic acid delivery and low cellular toxicity  Learn more>>
  • Animal Origin Free – High performance with maximum compatibility

Figures and Data

Copy Link Enlarge Image
TransIT-2020 Reagent Exhibits Higher Expression and Lower Cell Toxicity Compared to Other Transfection Reagents

TransIT®-2020 Reagent Exhibits Higher Expression and Lower Cellular Toxicity Compared to Other Transfection Reagents. Human umbilical vein endothelial cells (HUVEC) were transfected with a luciferase expression plasmid using the designated reagents at the reagent-to-DNA ratios indicated beneath each bar. Transfections were performed in 96-well plates using 0.1 µg of plasmid DNA per well. Luciferase expression (bar graph) and lactate dehydrogenase (LDH) levels (line graph) were measured at 24 hours post-transfection. LDH levels are reported as % cytotoxicity compared to cells alone and were measured using a commercially available colorimetric assay; all values at or below zero are represented as zero on graph. Error bars represent the standard deviation of triplicate wells.

Copy Link Enlarge Image
High Performance Plasmid Transfection of Primary Cells

High Performance Plasmid Transfection. Primary Human Small Epithelial Cells (HSAEpic) were transfected using TransIT®-2020 and an EGFP expression plasmid (4:1 reagent-to-DNA ratio). Images were taken 24 hours post-transfection using a Zeiss axiovert inverted fluorescence microscope.

Copy Link Enlarge Image
Superior Gene Expression in a Broad Spectrum of Cell Types

Superior Gene Expression in a Broad Spectrum of Cell Types. The indicated cell types were transfected in 96-well plates with a luciferase expression plasmid (0.1 µg/well) according to industry accepted testing protocols. Reagent to DNA ratios were optimized for each cell type: TransIT®-2020 (Mirus Bio, 2:1 or 3:1), FuGENE® HD (Roche, 3.5:1), Lipofectamine® 2000 (Life Technologies, 1.5:1, 3:1 or 5:1).  Luciferase activity was measured 24 hours post-transfection. Values were normalized to TransIT®-2020 and presented as a percentage of luciferase expression. FuGENE® is a registered trademark of Fugent LLC. Lipofectamine® is a trademark of Life Technologies Corporation.

Resources

Specifications

Storage Conditions:
All Configurations: Store at -20°C

Product Guarantee:
All Configurations: 1 year

Technical Product Literature


Additional Resources

COA Lookup

Download Certificates of Analysis

COO Lookup

Download Certificate of Origin

CRISPR Experimental Data
Preliminary Data: Western blot from non-clonal cell populations demonstrating efficient targeting of three genes of interest.

Testimonials

Using TransIT®-2020, we transfected HeLa cells in 6-well plates with 1.25 µg of the Zheng lab construct (pX330) from Addgene that harbors both a specific guide RNA against a recognition sequence in our gene of choice, and 1.25 µg of a donor plasmid with 1 kb of 5’ and 3’ homology sequence. We then selected the cells using puromycin and came across a population that harbored the modification we were interested in. Thank you so much for the sample of TransIT®-2020. Mirus has always been without exception the gold standard for me and why anyone else would want to use anything else is just beyond me.
Aviva Joseph
University of Massachusetts Medical School
I was using Lipofectamine® to transfect HEK cells and was only getting about 20% transfection rates but after using TransIT®-2020 it went from 20% to 70%! I highly recommend using this reagent. It was very easy to follow the protocol and I obtained high cell viability. (Review published in SelectScience)
Dr. Olivia George
Univeristy of New Mexico - Department of Molecular Genetics and Microbiology
...However, I did find a gem: The TransIT®-2020 reagent from Mirus Bio LLC. I tested five or six breast cancer cell lines, and in general, my transfection efficiency was 5-10 fold higher with the TransIT®-2020 reagent than with the "standards" - Lipofectamine®...with essentially no cell death. I also saw, for the first time ever, true 100% transfection efficiency of HEK293 cells - every last cell on the plate, glowing bright GFP-green.
Nicole Perry
Kontrogianni Lab, University of Maryland
TransIT®-2020 Transfection Reagent has been working well in our CRISPR genome editing experiments in HEK 293 cells. I appreciate the fact that the transfection protocol is straightforward, the toxicity appears to be low and we obtained high CRISPR knockout efficiency.
Steve Plouffe
Sanford Consortium for Regenerative Medicine
I recently tested TransIT®-2020 and TransIT®-LT1, and both reagents worked well in terms of their efficiency at transfecting human-derived iPS cells with CRISPR constructs and a fluorescent protein reporter. Through visual inspection, transfection efficiencies with TransIT®-2020 and TransIT®-LT1 were clearly higher than with Lipofectamine® 3000.
Fedir Kiskin
University of Cambridge
...We have been able to transfect BMDM’s with the TransIT®-2020 Transfection Reagent. Not only are my cells healthier, but I get good expression, and it is more cost effective to the Neon Transfection System that my lab traditionally uses. I have also been able to share these results with others that are now trying it with great success. It makes me look like a hero!
Jeffrey Fay
Hoffman Lab, University of Hawaii at Manoa
Our lab routinely works with primary human fibroblasts which are notoriously difficult to transfect, and we require a method that is non-toxic, reliable, and reproducible. TransIT®-2020 is the only reagent on the market that fits those criteria. In addition, TransIT®-2020 also transfects colon cancer cell lines HCT-116 and DLD1 with much higher efficiencies. Overall, the pace and quality of our research have improved since we started using TransIT®-2020.
John A. Burns
David Scicchitano Lab, New York University